BioCentury | Jan 4, 2018
Translation in Brief

New Therapeutic Targets and Biomarkers: December 2017

...help treat pancreatic cancer. Genentech Inc. unit of Roche (SIX:ROG; OTCQX:RHHBY) Distillery Therapeutics Cardiovascular Atherosclerosis Rho guanine nucleotide exchange factor 1...
BioCentury | Dec 13, 2017
Distillery Therapeutics

Cardiovascular

...leukocytes with normal ARHGEF1 expression. Next steps could include developing a leukocyte-specific ARHGEF1 inhibitor. TARGET/MARKER/PATHWAY: Rho guanine nucleotide exchange factor 1...
...email: gervaise.loirand@univ-nantes.fr Mark Zipkin Institut National de la Sante et de la Recherche Medicale (INSERM) Low-density lipoprotein receptor (LDLR) Rho guanine nucleotide exchange factor 1...
BioCentury | Jul 11, 2013
Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Cancer Ras; rho guanine nucleotide exchange factors (ARHGEFs; GEFs) An in vitro study suggests prolonged inhibition of interactions between Ras and GEFs could help treat...
BioCentury | Jun 20, 2013
Cover Story

Interfacing with Ras

A German team has identified a compound that disrupts a protein-protein interaction that localizes K-Ras to the cell membrane, thus inhibiting tumor growth. 1 The interface provides a new small molecule binding site for the...
BioCentury | Feb 14, 2013
Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Cancer Ras homolog gene family member A (RHOA); leukemia-associated Rho guanine nucleotide exchange factor (LARG) In vitro studies identified a small molecule inhibitor of the...
BioCentury | May 14, 2009
Targets & Mechanisms

Going after GEFs in cancer

Despite the association between mutations in Rho guanine nucleotide exchange factors and cancer, no companies are pursuing GEF inhibitors. Antagonizing the targets is challenging because it requires inhibiting a protein-protein interaction, a task for which...
BioCentury | Feb 19, 2009
Distillery Therapeutics

Indication: Cancer

This week in therapeutics Indication Target/ marker/pathway Summary Licensing status Publication and contact information Cancer Cancer Coiled-coil domain containing 88A (CCDC88A; GIV); Rho guanine nucleotide exchange factor (GEF; ARHGEF); G protein alpha inhibiting activity polypeptide...
BioCentury | Jun 5, 2008
Distillery Therapeutics

This Week in Therapeutics

This week in therapeutics Indication Target/ marker/pathway Summary Licensing status Publication and contact information Musculoskeletal disease Osteoporosis Rho guanine nucleotide exchange factor (GEF) 3 (ARHGEF3) A genome-wide association study suggests that ARHGEF3 plays a role...
Items per page:
1 - 8 of 8